Business Context and Reporting Period
MEDICINOVA INC filed a Form 8-K on April 1, 2011, to disclose a Japanese financial report ("Kessan Tanshin") filed with the Osaka Securities Exchange. This report supplements the Company's Annual Report on Form 10-K for the year ended December 31, 2010, by providing forward-looking financial forecasts for 2011.
Key Financial Metrics and Guidance
The filing provides management's financial results forecast for the interim period ending June 30, 2011, and the full fiscal year ending December 31, 2011. The filing text does not provide historical revenue, profit, or cash flow figures for the prior year; it only contains forward-looking estimates.
| Period | Revenues | Operating Loss | Net Loss |
|---|---|---|---|
| Interim (6 months ending June 30, 2011) | $0 | $(9,527,514) | $(11,410,664) |
| Full Year (ending Dec 31, 2011) | $0 | $(16,035,540) | $(19,358,402) |
Additional Metrics:
- Expected Loss Per Share (Full Year): $1.55 (basic and diluted), based on a weighted average of 12,527,965 shares.
- Anticipated Cash Burn: Less than $23.1 million for the fiscal year ending December 31, 2011 (includes original debt repayment schedule).
- Currency Translation: Supplementary Japanese yen statements were translated at 81.49 JPY per USD.
Material Changes and Outlook
The filing does not report material changes to historical financials but introduces a forecast indicating continued losses with no projected revenue for 2011. Management commentary highlights significant risks regarding the integration of the Avigen, Inc. acquisition and the combined ibudilast development programs. The Company is pursuing discussions with potential partners to secure strategic collaborations.
Risks and Contingencies:
- Uncertainty in clinical trial results and regulatory approvals.
- Reliance on third parties for manufacturing and clinical trials.
- Need to raise sufficient capital to complete product development plans.
- Potential impairments to the investment portfolio due to credit market conditions.
- Currency exchange rate fluctuations.
The Company explicitly states that independent auditors have not compiled or reviewed these forecasted results and assume no responsibility for their accuracy.
Investor Verification Checklist
- Verify the Company's actual cash position and runway against the projected $23.1 million cash burn.
- Confirm the status of strategic partnership discussions for the ibudilast program.
- Review the Form 10-K for the year ended December 31, 2010, for historical financial data not included in this 8-K.
- Monitor progress on the integration of Avigen, Inc. and the combined clinical development timeline.
- Assess the risk of capital raising needs given the projected net loss of approximately $19.4 million for 2011.